$CUE insider trading

Over the last 12 months, Cue Biopharma insiders reported 1 buy totaling $100K and 3 sales totaling $2.0M across SEC Form 4 filings.

$100K
$2.0M
4
4
0%
Side
$100K$1.0M$10MMay '26JunJulAug
Sarraf Pasha
Meluzio Michael Vincent
Ray Sumita
Lin Shao-Lee

All insider trades

Scroll the table sideways for price, value and marks.

Aug 13, 2026Ray Sumita▼ Sale8,829$30.09$266K-6.9%
Aug 13, 2026Meluzio Michael Vincent▼ Sale5,628$30.09$169K-10.3%
Aug 13, 2026Lin Shao-Lee▼ Sale58,258$27.58$1.6M-7.6%
Dec 30, 2025Sarraf Pasha▲ Buy323,857$0.31$100K

Every $CUE filing on this page is one API call away

The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Cue Biopharma filings can reach your inbox instead.

Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CUE feed.